Canadian Solar Inc. (NASDAQ:CSIQ) on July 7th, 2014 announced that its wholly owned subsidiary, Canadian Solar Solutions Inc., on June 30th, completed the sale of the 10 MW AC solar photovoltaic (PV) power plant “Val Caron” valued at over CAD 60 million to One West Holdings Ltd., an affiliate of Concord Green Energy. Canadian Solar Inc. (NASDAQ:CSIQ) stock performance was -3.19% in last session and finished the day at $29.73. Traded volume was 4.31million shares in the last session and the average volume of the stock remained 3.54million shares. The beta of the stock remained 3.10. Canadian Solar Inc. (NASDAQ:CSIQ) insider ownership is 31.09%.

Genetic Technologies Limited (ADR) (NASDAQ:GENE), a Melbourne, Australia-based genetics testing company announced today in a press release that it had received 1,096 patient samples for its BREVAGen breast cancer test in its latest quarter ended June 30. The company noted that the test samples received had increased 37% over the previous quarter ended in March, and reached a level seen in the last quarter of calendar year 2013. Genetic Technologies Limited (ADR) (NASDAQ:GENE) rose 11.76 percent to $1.14 Monday on volume of 3.07million shares. The intra-day range of the stock was $1.11 to $1.31. Genetic Technologies Limited (ADR) (NASDAQ:GENE) has a market capitalization of $18.07million.

Dendreon Corporation (NASDAQ:DNDN) on June 9 announced that John H. Johnson has informed the Board of Directors of his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson has resigned from the Board, effective June 3, 2014, and the Board has elected Douglas G. Watson, Dendreon’s lead independent director, as chairman of the Board.  Dendreon’s Board is working with an executive search firm to help identify Mr. Johnson’s successor. Mr. Johnson will serve as chief executive officer until August 15, 2014. Dendreon Corporation (NASDAQ:DNDN)’s stock on July 07, 2014 reported a increase of 1.75% to the closing price of $2.33. Its fifty two weeks range is $1.81 -$5.38. The total market capitalization recorded $372.93million. The overall volume in the last trading session was 2.92million shares. In its share capital, DNDN has 159.96million outstanding shares.

Arena Pharmaceuticals Inc (NASDAQ:ARNA) shares plunged Monday on news that its chief executive Jack Lief sold nearly 40 percent of his holdings in the company. Lief sold 223,525 shares on July 1 at $5.85 per share. The transaction was an “automatic sell” apparently triggered by a declining share price. On Monday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -9.42% to close the day at $5.29. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as -13.98%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is -14.95%.